According to a recent study, Epocrates, Inc. - an
) subsidiary - leads the digital health market in terms of medical
reference application reach on smartphones, for the fifth
consecutive year. However, following the announcement, shares of
athenahealth fell nearly 3.3% to close at $124.71 yesterday.
Epocrates is a provider of point-of-care digital solutions in the
healthcare industry. It was acquired by athenahealth in Mar, 2013.
The combined entity benefits from the unification of Epocrates'
mobile expertise, and knowledge and data from athenahealth's
Manhattan Research's "2014 Taking the Pulse U.S. Study" releases
reports on technology adoption and behavioral trends among U.S.
physicians. The study takes into account the opinion of more than
Per the key findings of the study, Epocrates is the number one
medical reference application on smartphone and tablet devices
among U.S. physician app users.
The study further revealed that Epocrates users are more likely to
use digital resources on their smartphones for professional
purposes than the average U.S. physician. 62% of Epocrates users
access clinical content through smartphones in between patient
consultations while 39% do the same while attending to patients.
The study also established that Epocrates physicians are frequent
users, evidenced by the statistics which reveals that nearly
one-third of the physicians launch the Epocrates app on their
smartphones at least thrice a day.
While drug references remain one of the top digital resources used
by physicians on a smartphone, the study holds that Epocrates users
are almost twice as likely as non-Epocrates users to access both
drug reference databases and clinical references.
Epocrates aims to provide heath care professionals state-of-the-art
service by helping them take efficient and confident decisions
while administering patient care. With continued innovation, it
seeks to add more value to providers and ultimately patients.
Going forward, athenahealth intends to advance Epocrates to the
next stage of mHeath care coordination and network connectivity,
while retaining focus on the core app.
Currently, athenahealth carries a Zacks Rank #3 (Hold). Some
better-ranked medical product stocks worth considering are
Eagle Pharmaceuticals Inc.
). All these stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ATHENAHEALTH IN (ATHN): Free Stock Analysis
NEUROMETRIX INC (NURO): Free Stock Analysis
CARDICA INC (CRDC): Free Stock Analysis Report
EAGLE PHARMACT (EGRX): Free Stock Analysis
To read this article on Zacks.com click here.